REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2017

Summary

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2017. Total revenues increased by 17.5% year-over-year to $4.29 billion, driven by robust growth in net product sales of EYLEA and significant increases in collaboration revenues from Sanofi and Bayer. Net income saw a substantial increase of 59.5% to $1.02 billion, with diluted earnings per share rising to $8.84 from $5.51 in the prior year period. This growth reflects continued strong demand for key products and successful advancement of strategic collaborations, indicating positive momentum for the company. The company's balance sheet also reflects healthy growth, with total assets increasing to $8.70 billion from $6.97 billion at the end of 2016, primarily due to increases in cash, marketable securities, and property, plant, and equipment. Total stockholders' equity significantly increased to $6.05 billion from $4.45 billion, driven by retained earnings. These financial highlights demonstrate a solid operational and financial footing for Regeneron, supporting its ongoing research and development efforts and commercialization of its product portfolio.

Key Highlights

• 1Total revenues increased by 17.5% to $4.29 billion for the nine months ended September 30, 2017.
• 2Net income grew by 59.5% to $1.02 billion for the same period.
• 3Diluted earnings per share improved to $8.84 from $5.51 in the prior year.
• 4EYLEA net product sales in the US increased by 11.4% year-over-year for the nine months.
• 5Sanofi collaboration revenue increased by 28.5% to $677.7 million.
• 6Bayer collaboration revenue increased by 13.7% to $640.9 million.
• 7Cash and cash equivalents increased significantly by $256.9 million to $792.1 million as of September 30, 2017.

Frequently Asked Questions